Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.
In this episode of Speaking of Urology®, Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 American Urological Association Annual meeting, which was held April 28-May 1 in Chicago, Illinois. Weiner is a urologic oncology fellow at the University of California, Los Angeles, and Talwar is a urologic oncology fellow at Vanderbilt University in Nashville, Tennessee.
This recap was originally presented by Dr. Weiner and Dr. Talwar during a live Twitter Spaces event held by Urology Times. In the discussion, Weiner and Talwar touch on the followed abstracts:
Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.